Compare Gigacloud Technology Inc (GCT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Neurocrine Biosciences Inc — how do they compare? Gigacloud Technology Inc trades at $51.52 (market cap $1.84B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.1× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| GCT | NBIX | |
|---|---|---|
Market Cap | $1.84B | $16.76B |
Sector | Technology | Health |
52-Week High | $53.25 | $185.50 |
52-Week Low | $25.44 | $123.10 |
Enterprise Value | $1.97B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $53.25, up 1.62% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.16 versus $0.90 expected, and maintains a 10.65% net income margin. Revenue growth is projected from $1.29B in 2025 to $1.5B in 2026, supported by positive cash flow generation of $120.10M in 2025.
The outlook remains positive given strong profitability metrics (32.34% ROE) and analyst consensus favoring Buy ratings (66.67%). Key risks include potential margin pressure from higher costs and competitive threats in the B2B logistics space. The stock's current valuation at 12.3x P/E appears reasonable relative to growth prospects, though technical indicators show overbought conditions with RSI above 85.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
